X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Lead Product(s): POZ-Apomorphine
Therapeutic Area: Neurology Product Name: SER-252
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Serina Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 26, 2024
Details:
The combined company will keep Serina name and trade on the New York Stock Exchange under the ticker "SER", and focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Lead Product(s): POZ-apomorphine
Therapeutic Area: Neurology Product Name: SER-252
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Serina Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 30, 2023
Details:
AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
Lead Product(s): AGEX-VASC1
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AGEX-VASC1
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lygenesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination July 23, 2021
Details:
The Ohio State University will use AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function.
Lead Product(s): AgeX-BAT1
Therapeutic Area: Endocrinology Product Name: AgeX-BAT1
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ohio State University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2021
Details:
LYG-LIV0001 is a regenerative mobile remedy comprising allogeneic hepatocytes suspended in a buffered cell preservation resolution which are transplanted into periduodenal lymph nodes.
Lead Product(s): LYG-LIV0001
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LYG-LIV0001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Lygenesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 02, 2021
Details:
ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImStem’s investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress syndrome from other causes.
Lead Product(s): IMS001
Therapeutic Area: Infections and Infectious Diseases Product Name: IMS001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ImStem Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 28, 2020
Details:
The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.
Lead Product(s): ESI human embryonic stem cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Pluristyx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
Details:
ImStem will obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome due to other causes.
Lead Product(s): IMS001
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: ImStem Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 02, 2020
Details:
Sernova to utilize AgeX’s UniverCyteTM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell PouchTM Platform.
Lead Product(s): Recombinant pluripotent stem cell-derived pancreatic islet beta cells
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sernova
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
Details:
ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.
Lead Product(s): IMS001
Therapeutic Area: Neurology Product Name: IMS001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
